William Blair analyst Matt Larew has maintained their bullish stance on WST stock, giving a Buy rating on April 14.
Matt Larew has given his Buy rating due to a combination of factors that reflect positively on West Pharmaceutical Services’ performance and future outlook. The company reported first-quarter results that exceeded both the firm’s and consensus expectations across key financial metrics. This strong performance was highlighted by a revenue of $698.0 million, surpassing the estimated figures, and an adjusted EPS of $1.45, which was significantly higher than the anticipated range.
Furthermore, the company has increased its guidance for 2025, projecting higher reported sales and adjusted EPS, which suggests confidence in its growth trajectory. Although the guidance raise is largely influenced by foreign exchange factors, the overall positive financial results and strategic adjustments indicate a robust core business. These elements combined have led Matt Larew to maintain a positive outlook on the stock, justifying the Buy rating.
According to TipRanks, Larew is an analyst with an average return of -8.0% and a 38.46% success rate. Larew covers the Healthcare sector, focusing on stocks such as 908 Devices, Repligen, and Maravai Lifesciences Holdings.
In another report released on April 14, Bank of America Securities also maintained a Buy rating on the stock with a $280.00 price target.